ARS Pharmaceuticals Inc. (SPRY)
12.67
0.18 (1.44%)
At close: Mar 31, 2025, 1:32 PM
ARS Pharmaceuticals Ratios Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| PE Ratio | 127.87 | -9.6 | -10.03 | -9.5 | -1.51K | -34.49 | -47.03 |
| PEG Ratio | -1.12 | 0.29 | -0.47 | -0.00 | 15.77 | -0.96 | n/a |
| PS Ratio | 11.47 | 17.39K | 258.99 | 34.92 | 90.16 | n/a | n/a |
| PB Ratio | 3.98 | 2.26 | 1.25 | -6.15 | -114.44 | -147.54 | 45.43 |
| P/FCF Ratio | 78.76 | -8.78 | -8.46 | -10.92 | 197.21 | -43.52 | -47.72 |
| P/OCF Ratio | 75.49 | -8.8 | -8.5 | -10.95 | 177.27 | -43.74 | -48.99 |
| OCF/S Ratio | 0.15 | -1.98K | -30.45 | -3.19 | 0.51 | n/a | n/a |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | -0.29 | -0.71 | -2.79 | 0.43 |
| Quick Ratio | 14.04 | 96.92 | 51.20 | 8.25 | 3.53 | 0.59 | 4.04 |
| Current Ratio | 14.26 | 96.92 | 51.01 | 7.42 | 3.21 | 0.59 | 4.04 |
| Asset Turnover | 0.25 | 0.00 | 0.00 | 0.09 | 0.68 | n/a | n/a |
| Interest Coverage | n/a | n/a | n/a | -183.53 | -16.17 | n/a | n/a |
| Return on Equity (ROE) | 0.03 | -0.24 | -0.12 | 0.65 | 0.08 | 4.28 | -0.97 |
| Return on Assets (ROA) | 0.02 | -0.23 | -0.12 | -0.33 | -0.04 | -1.53 | -0.64 |
| Return on Capital (ROIC) | -0.01 | -0.29 | -0.13 | -0.37 | -0.03 | 10.56 | -0.82 |
| Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit Margin | 100.00% | -143.33% | -1.22K% | -268.2% | 21.11% | n/a | n/a |
| Net Profit Margin | 8.97% | -181.22K% | -2.58K% | -367.65% | -5.97% | n/a | n/a |
| Pretax Profit Margin | 9.29% | -181.22K% | -2.64K% | -367.65% | -5.97% | n/a | n/a |
| Operating Profit Margin | -3.46% | -225.07K% | -2.7K% | -353.32% | -2.63% | n/a | n/a |
| FCF Margin | 14.57% | -198.14K% | -3.06K% | -319.94% | 45.72% | n/a | n/a |
| EBITDA Margin | -3.46% | -224.82K% | -2.7K% | -349.46% | -2.6% | n/a | n/a |